Implications of HIV drug resistance on irst- and second-line therapies in resource-limited settings: Report from a workshop organized by the Collaborative HIV and Anti-HIV Drug Resistance Network

Antiviral Therapy

Volumn 18, Issue 6, 2013, Pages 831-836

  Pillay, Deenan ^a   Deenan, Jan ^b   Bertagnolio, Silvia ^c   Boucher, Charles ^d   Brun Vezinet, Francoise ^e   Clotet, Bonaventura ^f   Giaquinto, Carlo ^g   Perno, Carlo F ^h  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e BICHAT HOSPITAL   (France)

^f HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^g UNIVERSITY OF PADOVA   (Italy)

^h UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; COST EFFECTIVENESS ANALYSIS; DISEASE SURVEILLANCE; DRUG COST; DRUG CROSS REACTIVITY; DRUG HALF LIFE; DRUG MONITORING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; NONHUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; SINGLE DRUG DOSE; VERTICAL TRANSMISSION; VIREMIA; VIRUS TRANSMISSION; DEVELOPING COUNTRY; HEALTH CARE PLANNING; HIV INFECTIONS; TRANSMISSION;

ANTI-HIV AGENTS; DEVELOPING COUNTRIES; DRUG RESISTANCE, VIRAL; HEALTH RESOURCES; HIV INFECTIONS; HUMANS;

EID: 84890364624     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2650     Document Type: Article

References (33)

1. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach (2010 revision). (15 July 2010. Accessed 14 October 2013.) Available from http://whqlibdoc.who.int/publications/2010/9789241599764-eng.pdf
2. World Health Organization. WHO HIV drug resistance report 2012. (Updated July 2012. Accessed 13 November 2012.) Available from www.who.int/hiv/pub/ drugresistance/report2012/en/index.html
3. World Health Organization. The strategic use of antiretrovirals to help end the HIV epidemic. (Updated July 2012. Accessed 13 November 2012.) Available from http://www.who.int/hiv/pub/arv/strategic-use/en/index.html
4. Cohen K, Meintjes G. Management of individuals requiring antiretroviral therapy and TB treatment. Curr Opin HIV AIDS 2010; 5:61-69.
5. White KL, Chen JM, Feng JY, et al. The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations. Antivir Ther 2006; 11:155-163.
6. Liverpool HIV Pharmacology Group. (Accessed 13 November 2012.) Available from www.hiv-druginteractions.org
7. Tang MW, Kanki PJ, Shafer RW. A review of the virological eficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy. Clin Infect Dis 2012; 54:862-875.
8. Back DJ, Burger DM, Flexner CW, Gerber JG. The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for oncedaily dosing. J Acquir Immune Deic Syndr 2005; 39 Suppl 1:S1-S23.
9. McColl DJ, Margot N, Chen SS, et al. Reduced emergence of the M184V/I resistance mutation when antiretroviralnaive subjects use emtricitabine versus lamivudine in regimens composed of two NRTIs plus the NNRTI efavirenz. HIV Clin Trials 2011; 12:61-70.
10. Quashie PK, Sloan RD, Wainberg MA. Novel therapeutic strategies targeting HIV integrase. BMC Med 2012; 10:34.
11. Adams JL, Greener BN, Kashuba AD. Pharmacology of HIV integrase inhibitors. Curr Opin HIV AIDS 2012; 7:390-400.
12. Messiaen P, Wensing AM, Fun A, et al. Clinical use of HIV integrase inhibitors: A systematic review and meta-analysis. PLoS ONE 2013; 8:e52562.
13. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral eficacy of AZT-3TC combination therapy. Science 1995; 269:696-699.
14. Götte M, Arion D, Parniak MA, Wainberg MA. The M184V mutation in the reverse transcriptase of human immunodeiciency virus type 1 impairs rescue of chainterminated DNA synthesis. J Virol 2000; 74:3579-3585.
15. Sunpath H, Wu B, Gordon M, et al. High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing irst-line regimen. AIDS 2012; 26:1679-1684.
16. Gilks CF, Walker AS, Dunn DT, et al. Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: A randomized controlled trial (SARA). Antivir Ther 2012; 17:1363-1373.
17. Bunupuradah T, Chetchotisakd P, Ananworanich J, et al. A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ ritonavir in patients failing NNRTI regimens: The HIV STAR study. Antivir Ther 2012; 17:1351-1361.
18. Crawford KW, Ripin DH, Levin AD, Campbell JR, Flexner C. Optimising the manufacture, formulation, and dose of antiretroviral drugs for more cost-eficient delivery in resource-limited settings: A consensus statement. Lancet Infect Dis 2012; 12:550-560.
19. World Health Organization. Programmatic update: use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. (Updated April 2012. Accessed 13 November 2012.) Available from http://www.who.int/hiv/pub/mtct/programmatic-update2012/en/index.html
20. Fogel JM, Mwatha A, Richardson P, et al. Impact of maternal and infant antiretroviral drug regimens on drug resistance in HIV-infected breastfeeding infants. Pediatr Infect Dis J 2013; 32:e164-e169.
21. Flynn PM, Mirochnick M, Shapiro DE, et al. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants. Antimicrob Agents Chemother 2011; 55:5914-5922.
22. World Health Organization. Antiretroviral therapy for HIV infection in infants and children: towards universal access. (Updated 2010. Accessed 13 November 2012.) Available from http://www.who.int/hiv/pub/paediatric/ infants2010/en/index.html
23. Paediatric European Network for Treatment of AIDS (PENTA). Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelinavir in children with HIV-1 who have not previously been treated: The PENTA 5 randomised trial. Lancet 2002; 359:733-740.
24. Gibb DM, Walker AS, Kaye S, et al. Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelinavir (the PENTA 5 trial). Antivir Ther 2002; 7:293-303.
25. Okwundu CI, Uthman OA, Okoromah CA. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. Cochrane Database Syst Rev 2012; 7:CD007189.
26. van de Vijver DA, Boucher CA. The risk of HIV drug resistance following implementation of pre-exposure prophylaxis. Curr Opin Infect Dis 2010; 23:621-627.
27. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329:1168-1174.
28. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-2599.
29. Reynolds S, Sendagire H, Newell K, et al. Routine VLM reduces the rate of accumulated genotypic resistance to commonly used ART in Uganda. 18th Conference on Retroviruses and Opportunistic Infections. 27 February-2 March 2011, Boston MA, USA. Abstract 53.
30. Taiwo B, Gallien S, Aga E, et al. Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during irst-line therapy. J Infect Dis 2011; 204:515-520.
31. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 2008; 13 Suppl 2:25-36.
32. Wittkop L, Gunthard HF, de Wolf F, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): A European multicohort study. Lancet Infect Dis 2011; 11:363-371.
33. Hamers RL, Wallis CL, Kityo C, et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: A multicentre observational study. Lancet Infect Dis 2011; 11:750-759.